Correlation Between Denali Therapeutics and Altimmune

Can any of the company-specific risk be diversified away by investing in both Denali Therapeutics and Altimmune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Denali Therapeutics and Altimmune into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Denali Therapeutics and Altimmune, you can compare the effects of market volatilities on Denali Therapeutics and Altimmune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Denali Therapeutics with a short position of Altimmune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Denali Therapeutics and Altimmune.

Diversification Opportunities for Denali Therapeutics and Altimmune

-0.44

Correlation Coefficient

Denali Therapeutics  Altimmune

Very good diversification

The 3 months correlation between Denali and Altimmune is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Denali Therapeutics and Altimmune in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Altimmune and Denali Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Denali Therapeutics are associated (or correlated) with Altimmune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Altimmune has no effect on the direction of Denali Therapeutics i.e., Denali Therapeutics and Altimmune go up and down completely randomly.

Pair Corralation between Denali Therapeutics and Altimmune

Given the investment horizon of 90 days Denali Therapeutics is expected to under-perform the Altimmune. But the stock apears to be less risky and, when comparing its historical volatility, Denali Therapeutics is 1.57 times less risky than Altimmune. The stock trades about -0.21 of its potential returns per unit of risk. The Altimmune is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  868.00  in Altimmune on September 23, 2024 and sell it today you would lose (43.00) from holding Altimmune or give up 4.95% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Denali Therapeutics  vs.  Altimmune

Denali Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Denali Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Altimmune

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Altimmune are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively inconsistent essential indicators, Altimmune unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Denali Therapeutics and Altimmune

The main advantage of trading using opposite Denali Therapeutics and Altimmune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Denali Therapeutics position performs unexpectedly, Altimmune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will offset losses from the drop in Altimmune's long position.

The idea behind Denali Therapeutics and Altimmune pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.